BioSpace News Archive

Drug Development

Novartis PARADIGMS Data Show Children And Adolescents With MS Had an 82% Lower Relapse Rate With Gilenya Vs. Interferon Beta-1a

Treatment with oral Gilenya resulted in an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years.

October 30, 2017
·
13 min read
Deals

Karolinska Development Divests Its Holdings in Xspray and Receives SEK 12.5 Million Directly and Additionally SEK 0.8 Million Via KCIF’s Sale

In September of 2015 Karolinska Development divested its holdings in Xspray to new owners.

October 30, 2017
·
2 min read
Relevium Files and Provides Comments on the Audited Consolidated Financial Statements for the Fiscal Year Ended June 30, 2017 and 2016

The Company reported significant changes to the Consolidated Statements of Financial Position, including an increase in total assets of $6,111,470 from $1,003,682 in 2016 to $7,115,152 in 2017.

October 30, 2017
·
4 min read